Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of cancer treatments? The latest research out of the journal Nature…

A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy has shown such promising results that researchers believe it may…

Cancer is one of the significant causes of death worldwide. As per the World Health Organization (WHO), one in six deaths in 2020 were caused…

Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its activity report for the December quarter of the current fiscal…

Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media to discuss the company’s innovative pipeline of personalised cancer therapies….

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a cash balance of $14.77 million, placing it in a strong…

With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR therapy into the clinic as it looks to unlock shareholder…

To fight the menace of cancer, there have been categorical and highly efficacious progress in the world of CAR-T therapy. Several companies have been contributing…

A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the appointment of two world-class experts – Dr. Marco Davila and…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and accelerate its proprietary OmniCAR platform after unveiling two high-profile additions to its scientific…